Generic Name and Formulations:
Neisseria meningitidis recombinant lipidated factor H binding protein (fHBP) variants 120mcg of Group B (subfamily A + subfamily B); per 0.5mL; susp for IM inj; contains polysorbate 80.
Indications for TRUMENBA:
Adults and Children:
<10yrs: not established. Give by IM inj in deltoid muscle of upper arm. 10–25yrs: 0.5mL given as 3-dose series according to a 0-, 2-, and 6-month schedule.
Severe allergic reaction after a previous dose of Trumenba.
Have epinephrine inj available. Immunosuppressed. Elderly. Pregnancy (Cat.B). Nursing mothers.
Concomitant other vaccines: see full labeling.
Inj site pain, fatigue, headache, muscle pain, chills, fever.
Single-dose prefilled syringes—5, 10
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Improving Performance of Everyday Activities Is Critical in Schizophrenia
- Analysis Finds Lithium Maintenance Most Effective as Monotherapy in Bipolar Disorder
- Web-Based Intervention Targets Parental Behaviors That May Affect Adolescent Anxiety, Depression
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Examining Associations Between Diabetes and Effects on Cognition
- Untreated Depression Common in Women of Childbearing Age
- Incidence of Psychiatric Disorders in Rheumatoid Arthritis
- Effect of Antidepressant Class, Dose on Pediatric Anxiety Disorders